Hoth Therapeutics is a biopharmaceutical company focused on developing therapies for dermatological disorders. Co.'s primary asset is a sublicense agreement with Chelexa Biosciences, Inc. (Chelexa) pursuant to which Chelexa has granted Co. sublicense to make, use, have made, import, provide for sale, and sell products based upon or involving the use of: topical compositions comprising a zinc chelator and gentamicin; and zinc chelators to inhibit biofilm formation (the BioLexa Platform), which rights were granted to Chelexa pursuant to a license agreement with the University of Cincinnati. The BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The HOTH stock yearly return is shown above.
The yearly return on the HOTH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HOTH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|